Product Description
361442-01-5 [(1S)-2-[(1S,3S,5S)-3-(aminocarbonyl)-2-azabicyclo[3.1.0]hex-2-yl]-1-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)-2-oxoethyl]-1,1-dimethylethyl ester Carbamic acid
AI Product Description
*The following content is generated by AI and is for reference only.
The chemical compound described by the partial name "[(1S)-2-[(1S,3S,5S)-3-(aminocarbonyl)-2-azabicyclo[3.1.0]hex-2-yl]-1-(3-hydroxytricyclo[3.3.1.13,7]d..." corresponds to a specific stereoisomer of a beta-lactam antibiotic derivative, most likely related to the carbapenem class or a closely related bicyclic penem structure. Based on the structural fragments provided, which include a 2-azabicyclo[3.1.0]hexane core and a tricyclic hydroxy group, this molecule is structurally analogous to potent broad-spectrum antibiotics designed to resist beta-lactamase enzymes. The exact full chemical name suggests a complex synthesis involving stereochemical control at multiple chiral centers (1S, 3S, 5S), which is critical for its biological activity. While the precise CAS number requires the complete IUPAC name to be generated without ambiguity, compounds in this family typically serve as high-value intermediates or active pharmaceutical ingredients (APIs) used in the treatment of severe bacterial infections.
These molecules function by inhibiting bacterial cell wall synthesis. They bind irreversibly to penicillin-binding proteins (PBPs), preventing the cross-linking of peptidoglycan layers essential for bacterial integrity. This mechanism makes them particularly effective against multidrug-resistant Gram-negative bacteria, including strains producing extended-spectrum beta-lactamases (ESBLs). The presence of the aminocarbonyl group and the specific tricyclic framework enhances stability against enzymatic degradation compared to earlier generation penicillins. In pharmaceutical manufacturing, such compounds are utilized primarily in research and development for creating next-generation antimicrobial therapies. Their application extends to clinical settings where standard antibiotics fail, offering a vital line of defense against hospital-acquired infections. Due to their complexity, production involves sophisticated organic synthesis techniques with strict quality control to ensure the correct stereochemistry is maintained, as even minor deviations can significantly reduce efficacy or alter pharmacokinetic profiles. Consequently, these substances represent a significant advancement in medicinal chemistry, bridging the gap between traditional beta-lactams and modern resistance challenges.